NVO

Novo Nordisk
NYSE

Real-time Quotes | Nasdaq Last Sale

64.64
+0.95
+1.49%
After Hours: 65.99 +1.35 +2.09% 17:08 08/07 EDT
OPEN
64.40
PREV CLOSE
63.69
HIGH
64.77
LOW
63.98
VOLUME
1.46M
TURNOVER
--
52 WEEK HIGH
68.96
52 WEEK LOW
48.60
MARKET CAP
114.06B
P/E (TTM)
25.79
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NVO stock price target is 70.73 with a high estimate of 72.00 and a low estimate of 69.45.

EPS

NVO News

More
Pharma Stock Roundup: ABBV, MRK Q2 Earnings & Coronavirus Updates in Focus
Zacks · 10h ago
Novo Nordisk's (NVO) Q2 Earnings Beat Estimates, Sales Miss
Novo Nordisk's (NVO) earnings surpass estimates but revenues miss the same in the second quarter of 2020.
Zacks · 1d ago
Novo Nordisk beats profit estimates, raises outlook despite stagnating sales
Denmark's Novo Nordisk <NOVOb.CO> posted a better-than-expected quarterly operating profit on Thursday and slightly lifted its full-year earnings outlook despite seeing sales stagnating due to fewer people taking up new treatments during the pandemic. "Despit
Reuters · 1d ago
Novo Nordisk's operating profit increased by 9% in Danish kroner and by 8% at constant exchange rates (CER) in the first six months of 2020
Financial report for the period 1 January 2020 to 30 June 2020 6 August 2020Novo Nordisk's operating profit increased by 9% in Danish kroner and by 8% at constant exchange rates (CER) in the first six months of 2020 * Sales increased by 8% in Danish kroner a
GlobeNewswire · 1d ago
Novo Nordisk tops estimates as costs fall
marketwatch.com · 2d ago
Novo Nordisk A/S – Share repurchase programme
Novo Nordisk A/S – Share repurchase programmeBagsværd, Denmark, 5 August 2020 – On 11 May 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (
GlobeNewswire · 2d ago
10 Biggest Biotechnology Companies
With Novo Nordisk at the top of the list, these are the 10 biggest biotechnology companies by 12-month trailing revenue.
Investopedia · 07/30 23:32
Novo, Roche Scored Highest Returns on Invested Capital
GuruFocus.com · 07/28 22:35

Industry

Pharmaceuticals
+0.19%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About NVO

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
More

Webull offers kinds of Novo Nordisk A/S (ADR) stock information, including NYSE:NVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVO stock methods without spending real money on the virtual paper trading platform.